|
Volumn 95, Issue 6, 2000, Pages 472-478
|
The p38 MAPK inhibitor, SB203580, abrogates ischaemic preconditioning in rat heart but timing of administration is critical
|
Author keywords
Infarct size; Ischaemic preconditioning; p38 MAPK; SB203580
|
Indexed keywords
4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE;
MITOGEN ACTIVATED PROTEIN KINASE;
SYNAPTOPHYSIN;
ANIMAL EXPERIMENT;
ANIMAL MODEL;
ANIMAL TISSUE;
ARTICLE;
CONTROLLED STUDY;
DRUG MECHANISM;
ENZYME ACTIVATION;
ENZYME PHOSPHORYLATION;
HEART INFARCTION PREVENTION;
HEART INFARCTION SIZE;
HEART PROTECTION;
ISCHEMIA;
ISOLATED HEART;
MALE;
NONHUMAN;
RAT;
TIME;
ANIMALS;
CORONARY CIRCULATION;
DRUG ADMINISTRATION SCHEDULE;
ENZYME INHIBITORS;
HEART;
IMIDAZOLES;
ISCHEMIC PRECONDITIONING;
MALE;
MITOGEN-ACTIVATED PROTEIN KINASES;
MYOCARDIAL INFARCTION;
MYOCARDIUM;
P38 MITOGEN-ACTIVATED PROTEIN KINASES;
PHOSPHORYLATION;
PRESSURE;
PYRIDINES;
RATS;
RATS, SPRAGUE-DAWLEY;
VENTRICULAR FUNCTION, LEFT;
|
EID: 0034537885
PISSN: 03008428
EISSN: None
Source Type: Journal
DOI: 10.1007/s003950070023 Document Type: Article |
Times cited : (96)
|
References (24)
|